IL1B and colitis: In a study utilizing an experimental colitis model in mice, disruption of GSDMD function was found to be correlated with increased therapeutic effects.17 A study by Bulek and colleagues18 revealed that interleukin-1β (IL-1β) release secondary to GSDMD was present in mice with colitis, which was also found to be correlated with an increase in disease severity.